Duke University

The United States Government as Represented by the Department of Veterans Affairs

Geoffrey S Ginsburg

Christopher W Woods

Joseph E Lucas

Ephraim L Tsalik

Ricardo Henao Giraldo

Jen-Tsan Ashley Chi

Thomas L Ortel

Thomas W Burke

Rachel A Myers

Deepak Voora

Vance Fowler

Sun Hee Ahn

Richard C Becker

Lawrence L Carin

William E Kraus

Elizabeth R Hauser

Alfred Hero

Christopher B Newgard

Svati Shah

L Kristin Newby

Aimee K Zaas

Erik Soderblom

Micah T McClain

The present disclosure provides methods and systems for processing a nucleic acid sample. The present disclosure also provides methods and systems for detecting (e.g., optically detecting) a pathogen in a sample. The methods provided herein may use nucleic acid amplification.

Methods and systems for processing a nucleic acid sample

The present disclosure provides methods for determining the presence or absence of and/or the etiology of an acute respiratory viral infection in a subject, as well as methods of treating the subject based on the determination, by measuring on a platform the expression levels of a pre-defined set of gene products.

Nasopharyngeal protein biomarkers of acute respiratory virus infection and methods of using same

The present disclosure provides methods for determining whether a subject has sepsis, or is at risk of developing sepsis, and methods of treating the subject based on the determination. Also provided are methods for determining an increased risk of mortality in a subject with sepsis or suspected of having sepsis, and methods of treating the subject based on the determination. Systems useful for the same are also provided.

Gene expression signatures useful to predict or diagnose sepsis and methods of using the same

Disclosed herein are biomarkers of platelet function and methods for assessing platelet function in response to antiplatelet therapy and for determining a prognosis, diagnosis, or risk identification in a patient by detecting at least one biomarker of platelet function in the patient as well as determining amounts thereof. The biomarkers may be used to identify a patient as a candidate for treatment with an antiplatelet agent and to monitor and adjust antiplatelet therapy in a patient.

Diagnostic markers for platelet function and methods of use

Disclosed herein are biomarkers useful for identifying and/or classifying bacterial infections in a subject.

Biomarkers for the molecular classification of bacterial infection

Disclosed herein are biomarkers of platelet function and methods for assessing platelet function in response to anti-platelet therapy and for determining a prognosis, diagnosis, or risk identification in a patient by detecting at least one biomarker of platelet function in the patient as well as determining amounts thereof. The biomarkers may be used to identify a patient as a candidate for treatment with an antiplatelet agent and to monitor and adjust antiplatelet therapy in a patient.

Methods of assessing the risk of cardiovascular disease in a subject by detecting the level of at least one metabolite in a sample from the subject are disclosed herein. The level of the metabolite is indicative of the risk of cardiovascular disease in the subject. The metabolites may be acylcarnitines, amino acids, ketones, free fatty acids or hydroxybutyrate. The cardiovascular disease may be risk of a cardiovascular event, presence of coronary artery disease or risk of development of coronary artery disease.

Predicting coronary artery disease and risk of cardiovascular events

Methods of identifying infectious disease infection prior to presentation of symptoms, assays for identifying genomic markers of infectious disease, and methods for diagnosing the underlying etiology of infectious disease.

Methods of identifying infectious disease and assays for identifying infectious disease

Growing community of inventors

Durham, NC, United States of America

Geoffrey S Ginsburg